The decreased muscle strength and fat mass associated with high-dose CCL2 are consistent with trends observed during cancer cachexia, as demonstrated in the 4T1 model here and in the Lewis lung carcinoma model (Raun et al., 2023). Here, CCL2 is linked to cancer.